CELL CULTURE PRODUCTION OF TOXOPLASMA GONDII TISSUE CYST

Award Information
Agency:
Department of Health and Human Services
Amount:
$730,970.00
Program:
SBIR
Contract:
N/A
Solitcitation Year:
N/A
Solicitation Number:
N/A
Branch:
N/A
Award Year:
1995
Phase:
Phase II
Agency Tracking Number:
18972
Solicitation Topic Code:
N/A
Small Business Information
Paravax Inc.
2301 Research Blvd, Fort Collins, CO, 80526
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 Irene Popiel
 (303) 493-7272
Business Contact
Phone: () -
Research Institution
N/A
Abstract
TOXOPLASMA GONDII STRAIN T-263 IS AN OOCYST NEGATIV GENETIC MUTANT THAT INDUCES IMMUNITY IN CATS TO WILD STRAINS WHEN TISSUE CYSTS OR BRADYZOITES ARE ADMINISTERED ORALLY. THE VACCINE POTENTIAL OF T-263 HAS BEEN PROVEN IN TWO SEPARATE EFFICACY STUDIES. USE OF THIS FELINE VACCINE WILL REDUCE OOCYST CONTAMINATION OF HOMES AND SURROUNDINGS THEREBY REDUCING ZOONOTIC TOXOPLASMOSIS IN HUMANS. PRODUCTION OF THE VACCINE IN MICE IS ECONOMICALLY AND PRACTICALLY UNACCEPTABLE. THUS, COMMERCIALIZATION DEPENDS ON THE DEVELOPMENT OF AN ECONOMIC METHOD FOR THE PRODUCTION OF TISSUE CYSTS/BRADYZOITES. THE OVERALL OBJECTIVE IS TO DEMONSTRATE THE FEASIBILITY OF PRODUCING T-263 TISSUE CYSTS (CONTAINING BRADYZOITES) IN CELL CULTURE. A LABORATORY-SCALE CELL CULTURE SYSTEM WILL BE OPTIMIZED FOR MAXIMAL CYST PRODUCTION BY USING STRATEGIES TO PREVENT CELL DESTRUCTION BY TACHYZOITES AND TO ENHANCE CYST PERSISTENCE. THE FEASIBILITY OF GENETIC SELECTION FOR ENHANCED TISSUE CYST FORMATION IN CELL CULTURE WILL ALSO BE EVALUATED. THIS WILL LEAD DIRECTLY INTO THE PHASE II PROGRAM OF PROCESS SCALE-UP AND DOWN-STREAM PROCESSING DEVELOPMENT. THIS NOVEL PRODUCTION TECHNOLOGY WILL HAVE IMMEDIATE APPLICATION TO THE COMMERCIALIZATION OF THE T-263 VACCINE.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government